Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Gemini Therapeutics, Inc.

Home Clinical Trial Sponsors and OrganizationsGemini Therapeutics, Inc.

Gemini Therapeutics, Inc.

CLOSED

600 Montgomery Street, Suite 4500 San Francisco, California 94111, 郑州市, 河南省, United Stateswww.geminitherapeutics.comPublic11–50 employeesEstablished: 2015-01-011-415-8774887 gemini@argotpartners.com

Also known as:

2020-06-25

Part of Disc Medicine

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

Clinical Trials

3

0 active

Approvals

0

Total approvals

Agencies

0

Regulatory bodies

Founded

2015

Overview

Trial Phase Distribution

Phase

Trials

Share

Phase 2

2

66.7%

Phase 1

1

33.3%

Trial Status Distribution

Completed

1

33.3%

Terminated

2

66.7%

Clinical Trials

Trials sponsored by this organization (3)

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration

Dec 202050 participants

A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Dry Age-related Macular Degeneration

Jul 202062 participants

First in Human Study to Evaluate the Safety and Tolerability of GEM103 in Geographic Atrophy Secondary to Dry Age Related Macular Degeneration

Dec 201912 participants

Approvals

No approval data available

News

No news articles found

On this page

Overview
Clinical Trials3
Approvals
News

Back to Organizations